Active, not recruitingPHASE1, PHASE2NCT02503423
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
Studying Aggressive primary cutaneous T-cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Taiho Oncology, Inc.
- Intervention
- ASTX660(drug)
- Enrollment
- 253 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2015 – 2027
Study locations (30)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- HonorHealth Research Institute, Scottsdale, Arizona, United States
- USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
- Cedars-Sinai Medical Center, Los Angeles, California, United States
- UC Davis Medical Center, Sacramento, California, United States
- Simlow Cancer Hospital at Yale, New Haven, Connecticut, United States
- Emory University winship Cancer Institute, Atlanta, Georgia, United States
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, United States
- The Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore, Maryland, United States
- Tufts Medical Center, Boston, Massachusetts, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Dartmouth-Hitchcock Medical Center (DHMC), Lebanon, New Hampshire, United States
- Summit Medical Group - Florham Park Campus/Atlantic Health, Florham Park, New Jersey, United States
- Roswell Park Cancer Institute, Buffalo, New York, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02503423 on ClinicalTrials.govOther trials for Aggressive primary cutaneous T-cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT05544968Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic MalignanciesMedical College of Wisconsin
- RECRUITINGPHASE1NCT07055477A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)National Cancer Institute (NCI)
- RECRUITINGPHASE1NCT07047885Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)H. Lee Moffitt Cancer Center and Research Institute
- RECRUITINGNANCT06860880Combating Cancer-Related Fatigue: A Personalized Supportive Care ProgramUNC Lineberger Comprehensive Cancer Center
- RECRUITINGPHASE1, PHASE2NCT07022964CD5 CAR T-Cell Therapy for r/r T-cell LymphomasBeijing GoBroad Hospital
- RECRUITINGNCT07132567Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result SurveillanceKyowa Kirin Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT06925464CD7 CAR T-Cell Therapy for r/r T-cell LymphomasBeijing GoBroad Hospital
- RECRUITINGPHASE1NCT06914037A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological MalignanciesTianjin Medical University Cancer Institute and Hospital
See all trials for Aggressive primary cutaneous T-cell lymphoma →